At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Joseph Gligorov, MD, PhD, of Sorbonne Université, Paris, France, discusses some of the difficulties with using Ki-67, a nuclear protein associated with cellular proliferation, as a predictive parameter for response to adjuvant chemotherapy in breast cancer patients.
This content is supported by Genomic Health, Inc.
